Literature DB >> 6234799

Hypertension and sudden death. Increased ventricular ectopic activity in left ventricular hypertrophy.

F H Messerli, H O Ventura, D J Elizardi, F G Dunn, E D Frohlich.   

Abstract

The present study was designed to detect and quantify cardiac arrhythmias in hypertensive patients with left ventricular hypertrophy. Continuous ambulatory electrocardiographic tracings and arterial pressure were recorded for 24 hours in 14 normotensive subjects, 10 patients with established essential hypertension without left ventricular hypertrophy, and 16 hypertensive patients with left ventricular hypertrophy by electrocardiographic criteria. Urinary excretion of norepinephrine was simultaneously measured over four successive four-hour and one eight-hour period. Patients with left ventricular hypertrophy had significantly more ventricular (but not atrial) premature contractions than those without left ventricular hypertrophy or than normotensive subjects. Five patients with left ventricular hypertrophy had episodes of more than 30 premature ventricular contractions per minute. Higher-grade ventricular ectopic activity such as coupled premature ventricular contractions was seen in two, and multifocal premature ventricular contractions were seen in three in the group with left ventricular hypertrophy. No difference in urinary catecholamine excretion rates among the three groups was seen. Left ventricular hypertrophy has been shown to be an independent risk factor for sudden death and acute myocardial infarction. Electrocardiographic monitoring of patients with left ventricular hypertrophy allows identification of those who have the highest risk and, therefore, require the most aggressive therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6234799     DOI: 10.1016/0002-9343(84)90430-3

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  43 in total

Review 1.  Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives?

Authors:  D J Sheridan; M P Kingsbury; N A Flores
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

Review 2.  βIIPKC and εPKC isozymes as potential pharmacological targets in cardiac hypertrophy and heart failure.

Authors:  Julio Cesar Batista Ferreira; Patricia Chakur Brum; Daria Mochly-Rosen
Journal:  J Mol Cell Cardiol       Date:  2010-10-28       Impact factor: 5.000

Review 3.  Reserpine: a relic from the past or a neglected drug of the present for achieving cost containment in treating hypertension?

Authors:  G J Magarian
Journal:  J Gen Intern Med       Date:  1991 Nov-Dec       Impact factor: 5.128

Review 4.  Cardiovascular risk factors in perspective.

Authors:  S G Carruthers
Journal:  Can Fam Physician       Date:  1993-02       Impact factor: 3.275

Review 5.  Left ventricular hypertrophy. Prevalence in older patients and management.

Authors:  E Paciaroni; A Fraticelli
Journal:  Drugs Aging       Date:  1995-04       Impact factor: 3.923

6.  Long-term treatment of spontaneously hypertensive rats with PD123319 and electrophysiological remodeling of left ventricular myocardium.

Authors:  Xiao Ying; Guan Kai-Pan; Long Wei-Qing; Peng Long-Yun; Wu De-Xi; Huang Zhi-Bin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-14       Impact factor: 3.000

7.  Exercise testing in individuals with morbid obesity.

Authors:  Luis D Fornitano; Moacir F Godoy
Journal:  Obes Surg       Date:  2008-10-02       Impact factor: 4.129

8.  Intramural Reentrant Ventricular Tachycardia in a Patient with Severe Hypertensive Left Ventricular Hypertrophy.

Authors:  Chin-Yu Lin; Fa-Po Chung; Yenn-Jiang Lin; Shih-Ann Chen
Journal:  Korean Circ J       Date:  2015-11-25       Impact factor: 3.243

Review 9.  Electrolyte abnormalities and ventricular arrhythmias.

Authors:  P V Caralis; E Perez-Stable
Journal:  Drugs       Date:  1986       Impact factor: 9.546

10.  Left ventricular hypertrophy regression during antihypertensive treatment.

Authors:  H Eichstaedt; O Danne; R J Schroeder; D Kreuz
Journal:  Clin Investig       Date:  1992
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.